M Singh1, J L Mathew, S Chandra, S Katariya, L Kumar. 1. Department of Paediatrics, Advanced Paediatrics Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. meenusingh4@rediffmail.com
Abstract
AIM: To compare intrapleural streptokinase and placebo in paediatric empyema. METHODS:Children with empyema greater than stage 5 receivedintrapleural streptokinase (n = 19) or normal saline (n = 21) along with intercostal drainage. Clinical and serial sonographic outcomes were compared. RESULTS: Although there was no difference in clinical and sonographic outcome, none of the children with stage 7 empyema (multi-loculated empyema) who received streptokinase developed pleural thickening 30 d later. CONCLUSION: There is no short-term clinical benefit of intrapleural streptokinase in paediatric empyema; this therapy may be reserved for those with stage 7 empyema to prevent pleural thickening in the long term.
RCT Entities:
AIM: To compare intrapleural streptokinase and placebo in paediatric empyema. METHODS:Children with empyema greater than stage 5 received intrapleural streptokinase (n = 19) or normal saline (n = 21) along with intercostal drainage. Clinical and serial sonographic outcomes were compared. RESULTS: Although there was no difference in clinical and sonographic outcome, none of the children with stage 7 empyema (multi-loculated empyema) who received streptokinase developed pleural thickening 30 d later. CONCLUSION: There is no short-term clinical benefit of intrapleural streptokinase in paediatric empyema; this therapy may be reserved for those with stage 7 empyema to prevent pleural thickening in the long term.
Authors: Morgan K Richards; Jarod P Mcateer; Todd C Edwards; Lucas R Hoffman; Matthew P Kronman; Dennis W Shaw; Adam B Goldin Journal: Surg Infect (Larchmt) Date: 2016-11-29 Impact factor: 2.150
Authors: Joanne M Langley; James D Kellner; Nataly Solomon; Joan L Robinson; Nicole Le Saux; Jane McDonald; Rolando Ulloa-Gutierrez; Ben Tan; Upton Allen; Simon Dobson; Heather Joudrey Journal: BMC Infect Dis Date: 2008-09-25 Impact factor: 3.090